Financial Analysis of Autolus Therapeutics (NASDAQ:AUTL) vs. Windtree Therapeutics (NASDAQ:WINT)


Autolus Therapeutics (NASDAQ:AUTL – Get Rating) and Windtree Therapeutics (NASDAQ:WINT – Get Rating) are both small-cap medical companies, but which business is superior? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Profitability

This table compares the net margins, return on equity and return on assets of Autolus Therapeutics and Windtree Therapeutics.

Net margins Return on equity return on assets
Therapeutic Autolus -6,551.06% -52.00% -42.38%
Windtree Therapeutic N / A -134.71% -80.04%

Analyst Recommendations

This is a summary of recent reviews of Autolus Therapeutics and Windtree Therapeutics, as provided by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Therapeutic Autolus 0 0 4 0 3.00
Windtree Therapeutic 0 0 1 0 3.00

Autolus Therapeutics currently has a consensus target price of $13.67, indicating a potential upside of 515.62%. Windtree Therapeutics has a consensus target price of $8.00, indicating a potential upside of 1,450.39%. Given the possible higher upside of Windtree Therapeutics, analysts clearly believe that Windtree Therapeutics is more favorable than Autolus Therapeutics.

Benefits and evaluation

This table compares the gross revenue, earnings per share and valuation of Autolus Therapeutics and Windtree Therapeutics.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Therapeutic Autolus $2.33 million 86.62 -$142.10 million ($1.86) -1.19
Windtree Therapeutic $200,000.00 75.87 -$67.64 million ($2.48) -0.21

Windtree Therapeutics has lower revenues, but higher profits than Autolus Therapeutics. Autolus Therapeutics trades at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and insider ownership

61.5% of Autolus Therapeutics shares are held by institutional investors. By comparison, 11.4% of Windtree Therapeutics shares are held by institutional investors. 16.1% of Windtree Therapeutics shares are held by insiders of the company. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a company will outperform the market over the long term.

Risk and Volatility

Autolus Therapeutics has a beta of 1.6, suggesting its stock price is 60% more volatile than the S&P 500. In comparison, Windtree Therapeutics has a beta of 0.29, suggesting its stock price is 71 % less volatile than the S&P 500.

Summary

Autolus Therapeutics beats Windtree Therapeutics on 8 out of 13 factors compared between the two stocks.

Autolus Therapeutics Company Profile (Get an assessment)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The Company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), an investigational programmed T-cell therapy targeting CD19 that is in a Phase 1b/2 clinical trial for the treatment of ALL in adults; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, an investigational programmed T-cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, an experimental programmed T-cell therapy, which is in the preclinical stage targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It is also focused on the development of AUTO5, a hematology product candidate, which is in preclinical development. The company was incorporated in 2014 and is based in London, UK.

Windtree Therapeutics Company Profile (Get an assessment)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutics for the treatment of acute cardiovascular disease and secondarily acute pulmonary disease. The Company’s principal development programs include istaroxime, which is in a Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as a Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, a KL4 surfactant aerosol, which is in a phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized surfactant KL4, which is in a Phase IIa clinical trial for the treatment of lung damage resulting from COVID-19; and Rostafuroxin which is in a phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with the Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, SA for the development, marketing and sale of a portfolio of potential surfactant KL4 products; and working with the Battelle Memorial Institute to develop its ADS for use in its Phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee’s Pharmaceutical Holdings Limited.



Get news and reviews for Autolus Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Autolus Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.

Sarah J. Greer